Cargando…

Clinical outcomes of HER2-positive metastatic breast cancer patients with brain metastasis treated with lapatinib and capecitabine: an open-label expanded access study in Korea

BACKGROUND: To evaluate efficacy in patients with brain metastasis (BM) on entry into the lapatinib expanded access program (LEAP). METHODS: LEAP is a worldwide, single-arm, open-label study. HER2-positive, locally-advanced or metastatic breast cancer patients with progression after an anthracycline...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ro, Jungsil, Park, Sohee, Kim, Sung- Bae, Kim, Tae You, Im, Young Hyuk, Rha, Sun Young, Chung, Joo Seop, Moon, Hanlim, Santillana, Sergio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3480888/ https://www.ncbi.nlm.nih.gov/pubmed/22839200 http://dx.doi.org/10.1186/1471-2407-12-322

Ejemplares similares

Correlation of HER2, p95HER2 and HER3 Expression and Treatment Outcome of Lapatinib plus Capecitabine in her2-Positive Metastatic Breast Cancer
por: Han, Sae-Won, et al.
Publicado: (2012)

Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases – the UK experience
por: Sutherland, S, et al.
Publicado: (2010)

Randomised Phase 2 study of lapatinib and vinorelbine vs vinorelbine in patients with HER2 + metastatic breast cancer after lapatinib and trastuzumab treatment (KCSG BR11-16)
por: Sim, Sung Hoon, et al.
Publicado: (2019)

Economic evaluation of third-line neratinib plus capecitabine versus lapatinib plus capecitabine with HER2+ metastatic breast cancer
por: Ren, Lanqi, et al.
Publicado: (2023)

BioPATH: A Biomarker Study in Asian Patients with HER2+ Advanced Breast Cancer Treated with Lapatinib and Other Anti-HER2 Therapy
por: Kim, Sung-Bae, et al.
Publicado: (2019)

Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial
por: Saura, Cristina, et al.
Publicado: (2020)

Lapatinib in combination with capecitabine in the management of ErbB2-positive (HER2-positive) advanced breast cancer
por: Kaufman, Bella, et al.
Publicado: (2008)

Randomized Open Label Phase III Trial of Irinotecan Plus Capecitabine versus Capecitabine Monotherapy in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane: PROCEED Trial (KCSG BR 11-01)
por: Park, In Hae, et al.
Publicado: (2019)

Brain Metastases of Her2-Positive Breast Cancer: A Case of 34 Months’ Remission with Lapatinib plus Capecitabine
por: Mailliez, Audrey, et al.
Publicado: (2014)

Efficacy of lapatinib combined with capecitabine in patients with HER2-positive metastatic breast cancer in a real-world study
por: Gui, Xinyu, et al.
Publicado: (2020)

Neratinib plus capecitabine versus lapatinib plus capecitabine as the third-line therapy for HER2-positive metastatic breast cancer in China: a cost-effectiveness analysis
por: Wu, Yue, et al.
Publicado: (2022)

Rapid symptomatic relief of HER2-positive gastric cancer leptomeningeal carcinomatosis with lapatinib, trastuzumab and capecitabine: a case report
por: Jiao, Xiao-Dong, et al.
Publicado: (2018)

Biomarker Analysis of the Phase III NALA Study of Neratinib + Capecitabine versus Lapatinib + Capecitabine in Patients with Previously Treated Metastatic Breast Cancer
por: Saura, Cristina, et al.
Publicado: (2021)

Cost-Effectiveness of Pyrotinib Plus Capecitabine versus Lapatinib Plus Capecitabine for the Treatment of HER2-Positive Metastatic Breast Cancer in China: A Scenario Analysis of Health Insurance Coverage
por: Bao, Yuwen, et al.
Publicado: (2022)

Nearly Complete Response of Brain Metastases from HER2 Overexpressing Breast Cancer with Lapatinib and Capecitabine after Whole Brain Irradiation
por: Oktay, Esin, et al.
Publicado: (2013)

Lapatinib plus capecitabine in treating HER2-positive advanced breast cancer: efficacy, safety, and biomarker results from Chinese patients
por: Xu, Bing-He, et al.
Publicado: (2011)

Early Adverse Events predict Survival Outcomes in HER2-positive Advanced Breast Cancer Patients treated with Lapatinib plus Capecitabine
por: Ang, Fang L.I., et al.
Publicado: (2020)

Trastuzumab emtansine vs lapatinib and capecitabine in HER2-positive metastatic breast cancer brain metastases: A real-world study
por: Sanglier, Thibaut, et al.
Publicado: (2023)

Lapatinib, a Dual EGFR and HER2 Tyrosine Kinase Inhibitor, Downregulates Thymidylate Synthase by Inhibiting the Nuclear Translocation of EGFR and HER2
por: Kim, Hwang-Phill, et al.
Publicado: (2009)

Lapatinib Plus Capecitabine in Women with HER-2–Positive Advanced Breast Cancer: Final Survival Analysis of a Phase III Randomized Trial
por: Cameron, David, et al.
Publicado: (2010)

Q-TWiST analysis of lapatinib combined with capecitabine for the treatment of metastatic breast cancer
por: Sherrill, B, et al.
Publicado: (2008)

Management of ErbB2-positive Breast Cancer: Insights from Preclinical and Clinical Studies with Lapatinib
por: Vogel, Charles, et al.
Publicado: (2010)

HSP90 Inhibitor, 17-DMAG, Alone and in Combination with Lapatinib Attenuates Acquired Lapatinib-Resistance in ER-positive, HER2-Overexpressing Breast Cancer Cell Line
por: Lee, Hye Jin, et al.
Publicado: (2020)

Development of prediction tools for diarrhea and rash in breast cancer patients receiving lapatinib in combination with capecitabine
por: Dranitsaris, George, et al.
Publicado: (2014)

Early relapse of inflammatory breast carcinoma treated with lapatinib and capecitabine: Ten years of complete response
por: Martin Huertas, Roberto, et al.
Publicado: (2019)

Pyrotinib Plus Vinorelbine Versus Lapatinib Plus Capecitabine in Patients With Previously Treated HER2-Positive Metastatic Breast Cancer: A Multicenter, Retrospective Study
por: Xie, Yizhao, et al.
Publicado: (2021)

Predictive Factors of Lapatinib and Capecitabine Activity in Patients with HER2-Positive, Trastuzumab-Resistant Metastatic Breast Cancer: Results from the Italian Retrospective Multicenter HERLAPAC Study
por: Gori, Stefania, et al.
Publicado: (2016)

An Open-Label, Randomized, Parallel, Phase III Trial Evaluating the Efficacy and Safety of Polymeric Micelle-Formulated Paclitaxel Compared to Conventional Cremophor EL-Based Paclitaxel for Recurrent or Metastatic HER2-Negative Breast Cancer
por: Park, In Hae, et al.
Publicado: (2017)

Analysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib+capecitabine (N+C) vs lapatinib+capecitabine (L+C) in patients with HER2+metastatic breast cancer (mBC) previously treated with two or more HER2-directed regimens
por: Dai, Ming Shen, et al.
Publicado: (2021)

Optimal tolerability and high efficacy of a modified schedule of lapatinib–capecitabine in advanced breast cancer patients
por: Gamucci, T., et al.
Publicado: (2013)

Fructus mume Extracts Alleviate Diarrhea in Breast Cancer Patients Receiving the Combination Therapy of Lapatinib and Capecitabine
por: Xing, Hua, et al.
Publicado: (2018)

A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer
por: Cristofanilli, Massimo, et al.
Publicado: (2012)

Lapatinib access into normal brain and brain metastases in patients with Her-2 overexpressing breast cancer
por: Saleem, Azeem, et al.
Publicado: (2015)

Combining lapatinib and pertuzumab to overcome lapatinib resistance due to NRG1-mediated signalling in HER2-amplified breast cancer
por: Leung, Wing-yin, et al.
Publicado: (2015)

Effective Treatment of Solitary Pituitary Metastasis with Panhypopituitarism in HER2-Positive Breast Cancer by Lapatinib
por: Park, Youngmok, et al.
Publicado: (2016)

Capecitabine and cisplatin (XP) combination systemic chemotherapy in heavily pre-treated HER2 negative metastatic breast cancer
por: Lee, Jieun, et al.
Publicado: (2017)

Lapatinib Plasma and Tumor Concentrations and Effects on HER Receptor Phosphorylation in Tumor
por: Spector, Neil L., et al.
Publicado: (2015)

Structural investigations on mechanism of lapatinib resistance caused by HER-2 mutants
por: Verma, Sharad, et al.
Publicado: (2018)

Impact of genomic alterations on lapatinib treatment outcome and cell-free genomic landscape during HER2 therapy in HER2+ gastric cancer patients
por: Kim, S T, et al.
Publicado: (2018)

Phase Ib/II single-arm trial evaluating the combination of everolimus, lapatinib and capecitabine for the treatment of HER2-positive breast cancer with brain metastases (TRIO-US B-09)
por: Hurvitz, Sara, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ehgof77tlibc8dlc4gc2mhdgig